ApiFix received FDA approval under a Humanitarian Device Exemption to market the MID-C Minimally Invasive Deformity Correction system to treat adolescent idiopathic scoliosis (AIS).
FDA claims this to be the first posterior non-fusion device to treat adolescents with idiopathic scoliosis.
MID-C was developed as a less invasive motion-preserving alternative to fusion to treat progressive scoliosis in a select group of AIS patients. The system provides permanent curve correction while retaining spine flexibility. Patient recovery is relatively pain-free and is measured in days, not months. The MID-C system acts as an “internal brace” with a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
ApiFix received FDA approval under a Humanitarian Device Exemption to market the MID-C Minimally Invasive Deformity Correction system to treat adolescent idiopathic scoliosis (AIS).
FDA claims this to be the first posterior non-fusion device to treat adolescents with idiopathic scoliosis.
MID-C was developed as a less invasive...
ApiFix received FDA approval under a Humanitarian Device Exemption to market the MID-C Minimally Invasive Deformity Correction system to treat adolescent idiopathic scoliosis (AIS).
FDA claims this to be the first posterior non-fusion device to treat adolescents with idiopathic scoliosis.
MID-C was developed as a less invasive motion-preserving alternative to fusion to treat progressive scoliosis in a select group of AIS patients. The system provides permanent curve correction while retaining spine flexibility. Patient recovery is relatively pain-free and is measured in days, not months. The MID-C system acts as an “internal brace” with a patented unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints, allowing additional post-operative correction over time.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
